Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
|
|
- Adam Bryant
- 5 years ago
- Views:
Transcription
1 The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007 to November 2010, a total of 109 BPH patients with aged 50 years or more were enrolled into the study. Inclusion criteria included significant LUTS and deteriorated QOL, with IPSS of 8 or more and its QOL score of 3 or more. The patients were randomly assigned to receive silodosin (8 mg/day, n = 58) or naftopidil (75 mg/day, n = 51) using a random number table envelope method. Exclusion criteria included estabbs_bs_banner International Journal of Urology (2013) 20, doi: /iju Short Communication Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial Kenya Yamaguchi, 1,2 Yutaka Aoki, 2 Tetsuo Yoshikawa, 2 Takahiko Hachiya, 2 Tadanori Saito 2 and Satoru Takahashi 1,2 1 Department of Urology, Nihon University School of Medicine, Tokyo, and 2 Sakura Clinical Study Group, Tokyo, Japan Abbreviations & Acronyms BPH = benign prostatic hyperplasia IIEF = International Index of Erectile Function IPSS = International Prostate Symptom Score LOCF = last observation carried forward LUTS = lower urinary tract PSA = prostate-specific antigen PVR = postvoid residual Qmax = peak urinary flow QOL = quality of life Correspondence: Satoru Takahashi M.D., Department of Urology, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo , Japan. takahashi.satoru@nihon-u.ac.jp Received 8 September 2012; accepted 10 March Online publication 3 June 2013 Abstract: This was a multicenter randomized trial to investigate the clinical efficacy and the impact on sexual function of alpha-1a selective silodosin and alpha-1d selective naftopidil for treatment of benign prostatic hyperplasia. A total of 97 patients with lower urinary tract /benign prostatic hyperplasia who had an International Prostate Symptom Score of 8 or more were randomly assigned to receive silodosin (8 mg/day, n = 53) or naftopidil (75 mg/day, n = 44). Before and 4, 8 and 12 weeks after treatment, International Prostate Symptom Score and its quality of life score were used to assess lower urinary tract. Also, International Index of Erectile Function-5, and an original questionnaire were used to evaluate erectile function and ejaculation for sexually active patients, respectively. The silodosin group showed advantages in terms of voiding and quality of life of International Prostate Symptom Score when compared with the naftopidil group. Both silodosin and naftopidil showed no significant effect on International Index of Erectile Function-5. A total of 23 sexually active patients in the silodosin group experienced more ejaculatory impairment than 21 patients in the naftopidil group, with a decrease of ejaculation volume (87% vs 40%, P = 0.003), prolonged time to ejaculation (56% vs 33%, P = 0.027) and decrease of orgasm (50% vs 39%, P = 0.027). These results suggest that alpha-1a selective blockers are more effective for voiding, whereas alpha-1d selective blockers offer a minor degree of ejaculatory dysfunction. Key words: alpha-1 adrenoreceptor subtypes, alpha-1 blockers, benign prostatic hyperplasia, ejaculation, sexual function. Introduction One of the adverse events in the use of alpha-1 blockers is ejaculatory disorder. Alpha-1 blockers differ in their likelihood of causing abnormal ejaculation. Alpha-1A selective blockers can result in reduced or absent seminal emission through inhibition of smooth muscle contraction. 1 An alpha-1 blocker, silodosin, is 162-fold more selective for alpha-1a than for alpha-1b, and is approximately 55-fold more selective for alpha-1a than for alpha-1d. 2 In contrast, naftopidil is an alpha-1d selective blocker, which has been recently reported to be less likely to induce ejaculatory disorders. 3 To investigate clinical efficacies and impacts on sexual function of these alpha-1 blockers in patients with BPH, we carried out a multicenter randomized trial. Methods The Japanese Urological Association
2 Silodosin vs naftopidil for BPH Table 1 Patient characteristics Silodosin group (n = 53) Naftopidil group (n = 44) P-value Age (years) Prostate volume (ml) PSA value Total IPSS Voiding symptom Storage symptom QOL index Qmax (ml/s) PVR (ml) Sexually active cases (n = 23) Sexually active cases (n = 21) IIEF Total ejaculation score Variables were summarized using the mean and standard deviation. lished prostate cancer, neurogenic bladder and any other complications that affect micturitional status. Patients who underwent prostate surgery, intervention or radiation therapy were also excluded. Out of 109 cases, 12 cases (5 cases of silodosin group and 7 cases of naftopidil group) dropped out of the study. The reasons for dropout were: the patient withdrew by their own decision in 10 and data missing after enrolment in two. Therefore, we analyzed 97 cases (53 cases of silodosin group and 44 cases of naftopidil group). Evaluated parameters included IPSS, QOL, Qmax (ml/s) and PVR (ml). The voiding included feeling of incomplete emptying, intermittency, slow stream and straining of the IPSS, whereas the storage included frequency, urgency and nocturia. For the evaluation of sexual function, we used the IIEF-5 and an original questionnaire of ejaculatory function. We considered patients who experienced at least one time of ejaculation as sexually active. The original questionnaire consisted of four questions, regarding ejaculation volume, time to ejaculation, orgasm and satisfaction (Appendix I). We collected information from questionnaires before treatment, and 4, 8 and 12 weeks after treatment, and measured the Qmax and PVR of each patient before and 12 weeks after treatment. Statistical analysis Some evaluations included cases where the LOCF imputation technique was used; that is, cases with a missing value that was replaced with the most recent valid non-missing value. The Wilcoxon test was used to evaluate changes of the scores and objective parameters between the two points of assessment (before vs 4, 8, 12 weeks) in each group. The Mann Whitney test was carried out to evaluate intergroup differences in changes from the baseline of the scores and parameters. P-values <0.05 were considered statistically significant and analyses were carried out using SPSS version 6 (IBM, Armonk, NY, USA). Results The patient characteristics are summarized in Table 1. Before treatment, 44% (n = 23) of patients taking silodosin and 47% (n = 21) of patients taking naftopidil were sexually active. No parameter showed a significant difference between the silodosin and naftopidil groups in the assessments before treatment. Efficacies of silodosin and naftopidil on LUTS Both silodosin and naftopidil significantly improved total IPSS and QOL at 4, 8 and 12 weeks after treatment (Table 2). At 12 weeks after administration, changes from the baseline of voiding and QOL in the silodosin group were significantly larger than those in the naftopidil group (Fig. 1a; P = 0014 and P = 0.023, respectively). In contrast, changes from the baseline of storage in IPSS of the naftopidil group tended to be larger than those in the silodosin group. However, they did not reach a statistical significance (Fig. 1a). Significant Qmax and PVR improvements were observed 12 weeks after treatment in both groups without intergroup differences (Table 3). Impacts of silodosin and naftopidil on sexual function At 12 weeks, 23 sexually active patients in the silodosin group showed a significant decrease from the baseline in every question of the IIEF-5 except that of confidence (from P > 0.03 to P > 0.001). When defining a decrease of 25% or 2013 The Japanese Urological Association 1235
3 K YAMAGUCHI ET AL. Table 2 Changes of total IPSS and QOL Before 4 Weeks 8 Weeks 12 Weeks P-value P-value P-value Silodosin n = 53 n = 48 n = 41 Naftopidil n = 44 n = 42 n = 38 Total IPSS silodosin naftopidil QOL Silodosin Naftopidil P-values are for the comparison versus before treatment. (a) 0% Total IPSS Voiding Storage QOL Table 3 Changes of total Qmax and PVR Before 12 Weeks P-value 20% 40% 60% P = P = P = 0.36 P = Qmax Silodosin Naftopidil <0.01 PVR Silodosin Naftopidil (b) 20% 0% 20% 40% 60% 80% Volume Time Orgasm Satisfaction P = P = P = P = 0.53 Fig. 1 (a) Changes in total IPSS, voiding, storage and QOL at 12 weeks after treatment (P = 0.014, 0.023). (b) Changes in ejaculation scores at LOCF (P = 0.003, 0.027, 0.027)., Silodosin;, naftopidil. more as deterioration, 4 all of these questions had deteriorated. In the naftopidil group, 21 sexually active patients showed a significant decrease from the baseline in every question of the IIEF-5 except for that of maintenance and completion (from P > 0.03 to P > 0.001). However, all decreases were smaller than 25% of baseline. Intergroup differences were not significant for changes from the baseline of each question (from P = 0.48 to P = 0.55). A significant impairment of ejaculation score was observed during the study period in the silodosin group. Self-assessed ejaculation volume, time to ejaculation, orgasm and satisfaction had all significantly deteriorated at 4, 8 and 12 weeks after treatment in the silodosin group (Table 4). At LOCF, the changes from baseline of volume, time and orgasm had deteriorated more in the silodosin group than in the naftopidil group (Fig. 1b; P = 0.003, 0.027, 0.027). Regarding the loss of ejaculation, 45% of sexually active 23 patients in the silodosin group replied that their ejaculation was lost at LOCF. In contrast, 8% of the 21 patients in the naftopidil group lost ejaculation. Discussion Accumulated knowledge of alpha-adrenoceptor subtypes led to the development of alpha-1 blockers that are more selective to prostatic smooth muscle, such as tamsulosin, which have fewer undesirable effects on the cardiovascular system. 5,6 As for the other adverse events, ejaculatory disorder occurred in 4.5% with tamsulosin, 0.3% with terazosin and 0% with alfuzosin. 7 The etiology has been reported to be retrograde ejaculation. 7 However, Hisasue et al. recently carried out a real-time observation of ejaculation using color Doppler ultrasound, and reported that the ejaculatory disorder induced by alpha-1 blocker is not retrograde ejaculation, but emission failure. 1 The effect of alpha-1 blockers on erectile function is still a controversial issue Demir et al. showed the effectiveness of doxazocin for LUTS patients with erectile dysfunction, and Yokoyama et al. reported an improvement of the The Japanese Urological Association
4 Silodosin vs naftopidil for BPH Table 4 Changes of ejaculation scores Before 4 Weeks 8 Weeks 12 Weeks P-value P-value P-value Silodosin n = 53 n = 48 n = 41 Naftopidil n = 44 n = 42 n = 38 Volume Silodosin Naftopidil Time Silodosin <0.001 <0.001 Naftopidil Orgasm Silodosin Naftopidil Satisfaction Silodosin < Naftopidil Total Silodosin Naftopidil P-values are for the comparison versus before treatment. IIEF-5 in patients receiving naftopidil treatment. 8,9 However, Chen observed no effect of tamsulosin for domains of the IIEF Similarly, we observed no improvement of the IIEF-5 for both naftopidil or silodosin treatment. Although intergroup differences of the two drugs were not evident, each IIEF-5 question, except for that of confidence, had obviously deteriorated in the silodosin group. It is possible that prolonged ejaculation time affected questions in the IIEF-5. There are a few questionnaires for ejaculatory function Shimizu et al. evaluated ejaculatory function by three questions including quality of orgasm, the number of the bulbocavernosus/pelvic muscle contraction and the amount of semen. 13 As their questionnaire is for healthy volunteers, it might not be fit for clinical use. Rosen et al. addressed a validated questionnaire of four questions that are very similar to ours. 12 They consist of volume, force, cum and bother, whereas ours consist of volume, time, orgasm and satisfaction. To date, there are no established questionnaires. Therefore, we should be prudent when using the original questionnaire without validation. As the results we obtained clearly identified a deterioration of ejaculatory function in patients taking silodosin, we should pay attention to this adverse event when prescribing alpha-1 blockers. When prescribing this drug for patients with voiding difficulty, it is necessary to obtain adequate consent for adverse events, especially in relation to ejaculation. Recent reports suggested that the efficacy of silodosin for voiding function is parallel to the degree of ejaculation disorder; that is, better efficacy is associated with worse ejaculation status. 14,15 We observed a similar tendency of each effect at LOCF, unless it did not attain statistical significance (P = 0.06). Further studies are warranted to identify the impacts of various alpha-1 blockers on sexual function. Conclusions The efficacy of the alpha-1a selective blocker, silodosin, on LUTS has advantages in relation to voiding and QOL of IPSS, whereas alpha-1d selective blockers cause a minor degree of ejaculatory dysfunction. Acknowledgments The Sakura Clinical Study Group includes the following institutions: Akiru Municipal Medical Center, Chigasaki Tokusyukai General Hospital, Higashimatsuyama Municipal Hospital, Itabashiku Ishikai Hospital, Kasukabe Municipal Hospital, Kawaguchi Municipal Medical Center, Nichidai Itabashi Hospital, Nichidai Nerima Hikarigaoka 2013 The Japanese Urological Association 1237
5 K YAMAGUCHI ET AL. Hospital, Surugadai Nichidai Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital, Tokyo Rinkai Hospital and Yokohama Central Hospital. Conflict of interest None declared. References 1 Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int. J. Urol. 2006; 13: Kaplan SA. Side effects of alpha-blocker use: retrograde ejaculation. Rev. Urol. 2009; 11: S Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn. J. Pharmacol. 1999; 79: Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: Takenaka T, Fujikura T, Honda K, Asano M, Niigata K. Discovery and development of tamsulosin hydrochloride, a new alpha 1-adrenoceptor antagonist. Yakugaku Zasshi 1995; 115: Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. 1982; 128: Debruyne FM. Alpha blockers: are all created equal? Urology 2000; 56: Demir O, Ozdemir I, Bozkurt O, Aslan G, Esen AA. The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract due to benign prostate hyperplasia. Asian J. Androl. 2009; 11: Yokoyama T, Hara R, Fukumoto K et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract and sexual function in males with benign prostatic hyperplasia. Int. J. Urol. 2011; 18: Chen Y, Wu X, Liu J, Tang W, Zhao T, Zhang J. Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. WorldJ.Urol.2011; 29: Ponholzer A, Madersbacher S. Lower urinary tract and erectile dysfunction; links for diagnosis, management and treatment. Int. J. Impot. Res. 2007; 19: Rosen RC, Catania JA, Althof SE et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 2007; 69: Shimizu F, Taguri M, Harada Y, Matsuyama Y, Sase K, Fujime M. Impact of dry ejaculation caused by highly selective alpha1a-blocker: randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men. J. Sex. Med. 2010; 7: Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010; 76: Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011; 14: Appendix I: Original index of ejaculation Over the past 4 weeks: Question Score How much was the amount Absence of ejaculation Decreased Fairly decreased Same as usual Fairly increased Increased of ejaculation volume? 2. How long was the time to Absence of ejaculation Prolonged Fairly prolonged Same as usual Fairly shortened Shortened ejaculation? 3. How was the orgasm? Absence of orgasm Decreased Fairly decreased Same as usual Fairly increased Increased 4. How satisfied with your ejaculation? Very dissatisfied Dissatisfied Fairly dissatisfied Mixed about equally satisfied and dissatisfied Fairly satisfied Satisfied Very satisfied The original index for evaluation of ejaculation consists of four questions regarding ejaculatory volume, time required for ejaculating, orgasm and satisfaction. The lowest sum is 0 and indicates the poorest status of ejaculation, whereas the highest sum is 21 and indicates the best status of it The Japanese Urological Association
Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
Sakata and Morita BMC Urology 2012, 12:29 RESEARCH ARTICLE Open Access Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia Koichi Sakata 1* and Tatsuo Morita 2
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationEffects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2014 August 32(2): 99-104 http://dx.doi.org/10.5534/wjmh.2014.32.2.99 Original Article Effects of Tamsulosin on Premature Ejaculation in Men with
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationProfile of Silodosin. Francesco Montorsi * Article info. Abstract
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 491 495 available at www.sciencedirect.com journal homepage: www.europeanurology.com Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationEjaculation. Emission. Ejection. Orgasm
Ejaculation Emission Ejection Orgasm Ejaculation sc T10-L2 S2-4 Emission: vas deferens, prostate, bladder neck Post. Urethra distention Ejection: Pelvic Floor / bulbocavernous muscle contraction Orgasm:
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationORIGINAL ARTICLE. Key words benign prostatic hyperplasia, bother, lower urinary tract symptoms, quality of life, tamsulosin
LUTS (2012) 4, 45 50 ORIGINAL ARTICLE Correlations among Lower Urinary Tract Symptoms, Bother, and Quality of Life in Patients with Benign Prostatic Hyperplasia and Associated Fluctuations with Tamsulosin
More informationVoiding Dysfunction. Hyo Serk Lee, Sae Woong Kim 1, Seung-June Oh 2, Myung-Soo Choo 3, Kyu-Sung Lee
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.3.178 Voiding Dysfunction Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationEffects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.10.697 Sexual Dysfunction/Male Infertility Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationComparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
LUTS (2017) 9, 176 186 ORIGINAL ARTICLE Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Masaki YOSHIDA, 1, Hideki ORIGASA,
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/02 Comparison of Silodosin with Tamsulosin in Patients with Symptomatic Benign Prostatic Hyperplasia: A Prospective,
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationSilodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy
EUROPEAN UROLOGY SUPPLEMENTS 10 (2011) 445 450 available at www.sciencedirect.com journal homepage: www.europeanurology.com Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy
More informationOriginal Research Article
International Surgery Journal Singh SN et al. Int Surg J. 218 May;():1866-1872 http://www.ijsurgery.com pissn 2349-33 eissn 2349-292 Original Research Article DOI: http://dx.doi.org/1.1823/2349-292.isj218199
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationLast Review Status/Date: December Summary
Section: Surgery Effective Date: January 15, 2016 Subject: Prostatic Urethral Lift Page: 1 of 9 Last Review Status/Date: December 2015 Summary Benign prostatic hyperplasia (BPH) is a common condition in
More informationTamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
J. Acad. Indus. Res. Vol. 1(11) April 2013 679 RESEARCH MANUSCRIPT ISSN: 2278-5213 Tamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
More informationProstate Artery Embolization
Prostate Artery Embolization in the office interventional suite Robert J. Kennedy, M.D. Interventional & Vascular Center Melbourne, Florida The speaker has no financial conflicts of interest to disclose.
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transurethral water vapour ablation for lower urinary tract symptoms caused by
More informationNational Institute for Health and Care Excellence. Lower Urinary Tract Symptoms Update Addendum Consultation Table 3 rd February 5 pm 3 rd March 2015
British Association of Urological Surgeons British Association of Urological Surgeons National Institute for Health and Care Excellence Lower Urinary Tract Symptoms Update Addendum Consultation Table 3
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationMasayuki TAKEDA, 1 Osamu NISHIZAWA, 2 Takeshi IMAOKA, 3 Yoji MORISAKI, 3 and Lars VIKTRUP 4 ORIGINAL ARTICLE
LUTS (2012) 4, 110 119 ORIGINAL ARTICLE Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki , Japan
BioMed Research International Volume 216, Article ID 4975851, 5 pages http://dx.doi.org/1.1155/216/4975851 Clinical Study Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary
More informationChin Kyung Doo, Myung-Soo Choo, Kyu-Sung Lee 1, Moon Kee Chung 2, Kwang Sung Park 3, Jae Seung Paick 4 and Tae Kon Hwang 5
대한배뇨장애요실금학회지 J Korean Continence Soc 2008;12:36-41 원저 Efficacy of terazosin for overactive bladder symptoms and sexual function in patients with overactive bladder and symptomatic benign prostatic hyperplasia:
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms
More informationOriginal Article - Sexual Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.9.608 Original Article - Sexual Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.9.608&domain=pdf&date_stamp=2014-09-16
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationProstatic Urethral Lift
Prostatic Urethral Lift Policy Number: 7.01.151 Last Review: 10/2018 Origination: 10/2015 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Prostatic
More informationEach value represents the mean ± S.E.M from at least three tests. Modified with permission from ref. 18.
Fig. 1 Chemical structure of naftopidil. Table 1 Affinity of naftopidil at the cloned human a 1-adrenoceptors. Each value represents the mean ± S.E.M from at least three tests. Modified with permission
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Prostatic Urethral Lift Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prostatic Urethral Lift Professional Institutional Original Effective Date:
More informationSexual dysfunction in male LUTS. M. Gacci Department of Urology, University of Florence
Sexual dysfunction in male LUTS M. Gacci Department of Urology, University of Florence Roma, 25-26 June, 2015 Cross-sectional population-based study of 4800 men (40 79 yr of age) UK, Netherlands, France,
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationSexual Dysfunction in Aging Men With Lower Urinary Tract Symptoms
Sexual Dysfunction and Infertility Sexual Dysfunction in Aging Men With Lower Urinary Tract Symptoms Darab Mehraban, Gholam Hossein Naderi, Seyed Reza Yahyazadeh, Mahdi Amirchaghmaghi Introduction: Our
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationProstatic Urethral Lift. Summary
Section: Surgery Effective Date: January 15, 2017 Subject: Prostatic Urethral Lift Page: 1 of 10 Last Review Status/Date: December 2016 Prostatic Urethral Lift Summary Benign prostatic hyperplasia (BPH)
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationWho Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
LUTS (2013) 5, 145 149 ORIGINAL ARTICLE Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign rostatic Hyperplasia? Jun OBATA, Kazuhiro
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationLasers in Urology. Sae Woong Choi, Yong Sun Choi, Woong Jin Bae, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae Kon Hwang, Sae Woong Kim
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.12.824 Lasers in Urology 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in
More informationFerdinando Fusco * , Massimiliano Creta, Nicola Longo, Francesco Persico, Marco Franco and Vincenzo Mirone
Fusco et al. BMC Urology (2018) 18:12 https://doi.org/10.1186/s12894-018-0326-7 RESEARCH ARTICLE Open Access Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary
More informationVOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS
VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS DR. FRANCIS LEE Voiding dysfunction Storage Emptying Common voiding dysfunction in elderly male Emptying BPH Storage Incontinence Overactive bladder Post-prostatectomy
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationIs Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study
Original Article Yonsei Med J 2016 Mar;57(2):407-418 pissn: 0513-5796 eissn: 1976-2437 Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationRelated Policies None
Medical Policy MP 7.01.151 BCBSA Ref. Policy: 7.01.151 Last Review: 12/27/2017 Effective Date: 03/01/2018 Section: Surgery End Date: 08/19/2018 Related Policies None DISCLAIMER Our medical policies are
More informationBenign Prostatic Hyperplasia: Update on Innovative Current Treatments
Benign Prostatic Hyperplasia: Update on Innovative Current Treatments Michael Ferrandino, MD As.soc Professor Director of Minimally Invasive Urologic Surgery Division of Urologic Surgery Duke University
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationProstatic Urethral Lift
Protocol Prostatic Urethral Lift (701151) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization No Review Dates: 05/17, 01/18 Preauthorization is not required. The following
More informationRelated Policies None
Medical Policy MP 7.01.151 Original Policy Date: August 2015 Last Review: 12/27/2017 Effective Date: 03/01/2018 Section: Surgery Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationThe patient, your co-pilot in assessing LUTS
The patient, your co-pilot in assessing LUTS Frank Van der Aa Leuven, Belgium This symposium is supported by Astellas Pharma Europe Ltd., including speaker honoraria and production of materials the slides
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationThe Pharmacological Profile of the a 1A -Adrenoceptor Antagonist Silodosin
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 486 490 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Pharmacological Profile of the a 1A -Adrenoceptor Antagonist Silodosin Martin
More informationConvective RF Water Vapor Energy Ablation Effectively Treats LUTS due to BPH, Preserves Erectile and Ejaculatory Function
1 Convective RF Water Vapor Energy Ablation Effectively Treats LUTS due to BPH, Preserves Erectile and Ejaculatory Function Nikhil Gupta, Tobias S. Köhler, Kevin T. McVary SIU School of Medicine Division
More informationEffect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic Study
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.12.840 Voiding Dysfunction/Female Urology Effect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationMedical Coverage Policy Prostatic Urethral Lifts
Medical Coverage Policy Prostatic Urethral Lifts EFFECTIVE DATE:12 01 2018 POLICY LAST UPDATED: 10 03 2017 OVERVIEW Benign prostatic hyperplasia is a common condition in older men that can lead to increased
More informationTreatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
510732JMHXXX10.1177/1557988313510732American Journal of Men s HealthSchoenfeld et al. research-article2013 Article Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia American
More informationEuropean Urology 48 (2005)
European Urology European Urology 48 (2005) 269 276 BPH/Prostatic Diseases Evaluation of Male Sexual Function in Patients with Lower UrinaryTract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia
More informationProstatitis: overview and assessment of pain outcomes and implications for inclusion criteria. Michel Pontari IMMPACT-XX Meeting July 13, 2017
Prostatitis: overview and assessment of pain outcomes and implications for inclusion criteria Michel Pontari IMMPACT-XX Meeting July 13, 2017 NIDDK Classification of Prostatitis 1 Type I: Acute Bacterial
More information